NEURONES (NRO.PA) Fundamental Analysis & Valuation

EPA:NRO • FR0004050250

Current stock price

34.25 EUR
-0.2 (-0.58%)
Last:

This NRO.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. NRO.PA Profitability Analysis

1.1 Basic Checks

  • In the past year NRO was profitable.
  • NRO had a positive operating cash flow in the past year.
  • NRO had positive earnings in each of the past 5 years.
  • NRO had a positive operating cash flow in each of the past 5 years.
NRO.PA Yearly Net Income VS EBIT VS OCF VS FCFNRO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

1.2 Ratios

  • NRO has a better Return On Assets (7.06%) than 76.06% of its industry peers.
  • With a decent Return On Equity value of 13.65%, NRO is doing good in the industry, outperforming 64.79% of the companies in the same industry.
  • The Return On Invested Capital of NRO (11.38%) is better than 74.65% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NRO is in line with the industry average of 10.82%.
Industry RankSector Rank
ROA 7.06%
ROE 13.65%
ROIC 11.38%
ROA(3y)7.25%
ROA(5y)6.8%
ROE(3y)13.74%
ROE(5y)12.58%
ROIC(3y)12.21%
ROIC(5y)11.57%
NRO.PA Yearly ROA, ROE, ROICNRO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • The Profit Margin of NRO (6.09%) is better than 67.61% of its industry peers.
  • NRO's Profit Margin has been stable in the last couple of years.
  • With a decent Operating Margin value of 8.90%, NRO is doing good in the industry, outperforming 66.20% of the companies in the same industry.
  • NRO's Operating Margin has been stable in the last couple of years.
  • NRO has a Gross Margin of 99.93%. This is amongst the best in the industry. NRO outperforms 95.77% of its industry peers.
  • NRO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.9%
PM (TTM) 6.09%
GM 99.93%
OM growth 3Y-3.33%
OM growth 5Y-0.03%
PM growth 3Y-0.09%
PM growth 5Y1.44%
GM growth 3Y0%
GM growth 5Y0%
NRO.PA Yearly Profit, Operating, Gross MarginsNRO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

9

2. NRO.PA Health Analysis

2.1 Basic Checks

  • NRO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • NRO has about the same amout of shares outstanding than it did 1 year ago.
  • NRO has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for NRO has been reduced compared to a year ago.
NRO.PA Yearly Shares OutstandingNRO.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
NRO.PA Yearly Total Debt VS Total AssetsNRO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 4.17 indicates that NRO is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.17, NRO belongs to the best of the industry, outperforming 85.92% of the companies in the same industry.
  • NRO has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.57, NRO belongs to the best of the industry, outperforming 88.73% of the companies in the same industry.
  • NRO has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.08, NRO belongs to the top of the industry, outperforming 84.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.57
Altman-Z 4.17
ROIC/WACC1.46
WACC7.82%
NRO.PA Yearly LT Debt VS Equity VS FCFNRO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.3 Liquidity

  • NRO has a Current Ratio of 2.31. This indicates that NRO is financially healthy and has no problem in meeting its short term obligations.
  • NRO has a better Current ratio (2.31) than 94.37% of its industry peers.
  • NRO has a Quick Ratio of 2.31. This indicates that NRO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.31, NRO belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
NRO.PA Yearly Current Assets VS Current LiabilitesNRO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

4

3. NRO.PA Growth Analysis

3.1 Past

  • NRO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.44%.
  • NRO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.23% yearly.
  • Looking at the last year, NRO shows a small growth in Revenue. The Revenue has grown by 7.39% in the last year.
  • The Revenue has been growing by 9.70% on average over the past years. This is quite good.
EPS 1Y (TTM)4.44%
EPS 3Y11.55%
EPS 5Y11.23%
EPS Q2Q%-7.43%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y11.8%
Revenue growth 5Y9.7%
Sales Q2Q%5.42%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.04% on average over the next years. This is quite good.
  • Based on estimates for the next years, NRO will show a small growth in Revenue. The Revenue will grow by 5.57% on average per year.
EPS Next Y4.76%
EPS Next 2Y6.9%
EPS Next 3Y8.74%
EPS Next 5Y8.04%
Revenue Next Year6.99%
Revenue Next 2Y6.24%
Revenue Next 3Y6.18%
Revenue Next 5Y5.57%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NRO.PA Yearly Revenue VS EstimatesNRO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
NRO.PA Yearly EPS VS EstimatesNRO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

4

4. NRO.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.47 indicates a correct valuation of NRO.
  • The rest of the industry has a similar Price/Earnings ratio as NRO.
  • The average S&P500 Price/Earnings ratio is at 25.61. NRO is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 14.13, NRO is valued correctly.
  • NRO's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.79, NRO is valued a bit cheaper.
Industry RankSector Rank
PE 16.47
Fwd PE 14.13
NRO.PA Price Earnings VS Forward Price EarningsNRO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NRO indicates a rather cheap valuation: NRO is cheaper than 88.73% of the companies listed in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as NRO.
Industry RankSector Rank
P/FCF 11.53
EV/EBITDA 3.81
NRO.PA Per share dataNRO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • NRO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.46
PEG (5Y)1.47
EPS Next 2Y6.9%
EPS Next 3Y8.74%

7

5. NRO.PA Dividend Analysis

5.1 Amount

  • NRO has a Yearly Dividend Yield of 4.02%, which is a nice return.
  • Compared to an average industry Dividend Yield of 2.78, NRO pays a bit more dividend than its industry peers.
  • NRO's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 4.02%

5.2 History

  • On average, the dividend of NRO grows each year by 82.05%, which is quite nice.
Dividend Growth(5Y)82.05%
Div Incr Years3
Div Non Decr Years3
NRO.PA Yearly Dividends per shareNRO.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • NRO pays out 57.47% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • NRO's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP57.47%
EPS Next 2Y6.9%
EPS Next 3Y8.74%
NRO.PA Yearly Income VS Free CF VS DividendNRO.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NRO.PA Dividend Payout.NRO.PA Dividend Payout, showing the Payout Ratio.NRO.PA Dividend Payout.PayoutRetained Earnings

NRO.PA Fundamentals: All Metrics, Ratios and Statistics

NEURONES

EPA:NRO (3/26/2026, 5:29:20 PM)

34.25

-0.2 (-0.58%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)03-11
Earnings (Next)05-06
Inst Owners12.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap833.30M
Revenue(TTM)832.18M
Net Income(TTM)50.68M
Analysts84
Price Target53.04 (54.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.02%
Yearly Dividend1.2
Dividend Growth(5Y)82.05%
DP57.47%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.76%
EPS NY rev (3m)4.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE 16.47
Fwd PE 14.13
P/S 1
P/FCF 11.53
P/OCF 9.89
P/B 2.24
P/tB 2.7
EV/EBITDA 3.81
EPS(TTM)2.08
EY6.07%
EPS(NY)2.42
Fwd EY7.08%
FCF(TTM)2.97
FCFY8.68%
OCF(TTM)3.46
OCFY10.12%
SpS34.2
BVpS15.26
TBVpS12.69
PEG (NY)3.46
PEG (5Y)1.47
Graham Number26.72
Profitability
Industry RankSector Rank
ROA 7.06%
ROE 13.65%
ROCE 15.78%
ROIC 11.38%
ROICexc 28.14%
ROICexgc 41.95%
OM 8.9%
PM (TTM) 6.09%
GM 99.93%
FCFM 8.69%
ROA(3y)7.25%
ROA(5y)6.8%
ROE(3y)13.74%
ROE(5y)12.58%
ROIC(3y)12.21%
ROIC(5y)11.57%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.96%
ROCE(5y)16.06%
ROICexgc growth 3YN/A
ROICexgc growth 5Y9.54%
ROICexc growth 3YN/A
ROICexc growth 5Y6.91%
OM growth 3Y-3.33%
OM growth 5Y-0.03%
PM growth 3Y-0.09%
PM growth 5Y1.44%
GM growth 3Y0%
GM growth 5Y0%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 0.57
Debt/EBITDA 0.32
Cap/Depr 66.65%
Cap/Sales 1.44%
Interest Coverage 250
Cash Conversion 91.59%
Profit Quality 142.65%
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z 4.17
F-Score7
WACC7.82%
ROIC/WACC1.46
Cap/Depr(3y)79.83%
Cap/Depr(5y)65.86%
Cap/Sales(3y)1.84%
Cap/Sales(5y)1.6%
Profit Quality(3y)115.8%
Profit Quality(5y)139.08%
High Growth Momentum
Growth
EPS 1Y (TTM)4.44%
EPS 3Y11.55%
EPS 5Y11.23%
EPS Q2Q%-7.43%
EPS Next Y4.76%
EPS Next 2Y6.9%
EPS Next 3Y8.74%
EPS Next 5Y8.04%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y11.8%
Revenue growth 5Y9.7%
Sales Q2Q%5.42%
Revenue Next Year6.99%
Revenue Next 2Y6.24%
Revenue Next 3Y6.18%
Revenue Next 5Y5.57%
EBIT growth 1Y0.63%
EBIT growth 3Y8.08%
EBIT growth 5Y9.67%
EBIT Next Year22.37%
EBIT Next 3Y14.47%
EBIT Next 5Y11.67%
FCF growth 1Y13.36%
FCF growth 3Y7.7%
FCF growth 5Y6.25%
OCF growth 1Y11.51%
OCF growth 3Y9.37%
OCF growth 5Y6.59%

NEURONES / NRO.PA Fundamental Analysis FAQ

What is the fundamental rating for NRO stock?

ChartMill assigns a fundamental rating of 7 / 10 to NRO.PA.


What is the valuation status for NRO stock?

ChartMill assigns a valuation rating of 4 / 10 to NEURONES (NRO.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for NEURONES?

NEURONES (NRO.PA) has a profitability rating of 7 / 10.


How financially healthy is NEURONES?

The financial health rating of NEURONES (NRO.PA) is 9 / 10.


Can you provide the expected EPS growth for NRO stock?

The Earnings per Share (EPS) of NEURONES (NRO.PA) is expected to grow by 4.76% in the next year.